KALAMAZOO – AureoGen Biosciences has announced the addition of two world-renowned German scientists to their staff, greatly enhancing the company?s research capabilities.
Dr. Torsten Stachelhaus and Dr. Katrin Eppelmann bring with them expertise is in natural products, with a special emphasis on the biology, biochemistry and genetics of cyclic peptide-producing organisms. The two researchers will play a major role in AureoGen?s efforts to generate new and novel drugs through genetic engineering of medicinally active natural products-producing organisms.
AureoGen is a research-based biotech company founded in August of 2003 by Ake Elhammer, Ph.D. and Jerry Slightom, Ph.D., both former Pharmacia scientists. AureoGen?s current focus in on novel antibiotics, with a special emphasis on drugs for treatment of systemic fungal infections. The company is located in the Southwest Michigan Innovation Center.
AureoGen is privately owned and has attracted funding from the Michigan Economic Development Corporation, the National Institutes of Health Small Business Innovative Research program, the National Institute of Standards and Technology Advanced Technology Research program and the Western Michigan University Bioscience Research and Commercialization Center.
